CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-κB

Blood

Volumn 97, Issue 11, 2001, Pages 3596-3604

  Lee, Im Soon ^a,b,c,d   Kirn, Min Kyung ^a,b,c,d   Choi, Eun Young ^a,b,c,d   Mehl, Anja ^a,b,c,d   Jung, Kyeong Cheon ^a,b,c,d   Gil, Min Chan ^a,b,c,d   Rowe, Martin ^a,b,c,d   Park, Seong Hoe ^a,b,c,d  

^a Seoul National University College of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

^c DiNonA Inc   (South Korea)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD99 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; TRANSCRIPTION FACTOR SP1;

ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; EPSTEIN BARR VIRUS; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; REED STERNBERG CELL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 0035383791     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3596     Document Type: Article

References (59)

1. Goodfellow P, Banting G, Levy R, Povey S, McMichael A. A human X-linked antigen defined by a monoclonal antibody. Somatic Cell Genet. 1980; 6:777-787.
2. Banting GS, Pym B, Goodfellow PN. Biochemical analysis of an antigen produced by both human sex chromosomes. EMBO J. 1985;4:1967-1972.
3. Goodfellow P, Banting G, Sheer D, et al. Genetic evidence that a Y-linked gene in man is homologous to a gene on the X chromosome. Nature. 1983;302:346-349.
4. Choi EY, Park WS, Jung KC, et al. Engagement of CD99 induces up-regulation of TCR and MHC class I and II molecules on the surface of human thymocytes. J Immunol. 1998;161:749-754.
5. Hahn JH, Kim MK, Choi EY, et al. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol. 1997;159:2250-2258.
6. Sohn HW, Choi EY, Kim SH, et al. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells. Am J Pathol. 1998;153:1937-1945.
7. Waclavicek M, Majdic O, Stulnig T, et al. CD99 engagement on human peripheral blood T cells results in TCR/CD3-dependent cellular activation and allows for Th1-restricted cytokine production. J Immunol. 1998;161:4671-4678.
8. Wingett D, Forcier K, Nielson CP. A role for CD99 in T cell activation. Cell Immunol. 1999;193:17-23.
9. Kim SH, Choi EY, Shin YK, et al. Generation of cells with Hodgkin's and Reed-Sternberg phenotype through down-regulation of CD99 (Mic2). Blood. 1998;92:4287-4295.
10. Goodfellow PJ, Darling SM, Thomas NS, Goodfellow PN. A pseudoautosomal gene in man. Science. 1986;234:740-743.
11. Gabriel-Robez O, Rumpler Y, Ratomponirina C, et al. Deletion of the pseudoautosomal region and lack of sex-chromosome pairing at pachytene in two infertile men carrying an X;Y translocation. Cytogenet Cell Genet. 1990;54:38-42.
12. Smith MJ, Goodfellow PJ, Goodfellow PN. The genomic organisation of the human pseudoautosomal gene MIC2 and the detection of a related locus. Hum Mol Genet. 1993;2:417-422.
13. Goodfellow PJ, Mondello C, Darling SM, et al. Absence of methylation of a CpG-rich region at the 5′ end of the MIC2 gene on the active X, the inactive X, and the Y chromosome. Proc Natl Acad Sci U S A. 1988;85:5605-5609.
14. Braghetti A, Piazzi G, Lanfranco L, Mondello C. Multiple DNA-protein interactions at the CpG island of the human pseudoautosomal gene MIC2. Somat Cell Mol Genet. 1993;19:51-63.
15. Mondello C, Goodfellow PJ, Goodfellow PN. Analysis of methylation of a human X located gene which escapes X inactivation. Nucleic Acids Res. 1988;16:6813-6824.
16. Kim SH, Shin YK, Lee I-S, et al. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood. 2000;95:294-300.
17. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985; 43:831-840.
18. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene. 1995;10:549-560.
19. Wang F, Gregory C, Sample C, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol. 1990; 64:2309-2318.
20. Wang D, Liebowitz D, Wang F, et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol. 1988; 62:4173-4184.
21. Rowe M, Peng-Pilon M, Huen DS, et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol. 1994;68:5602-5612.
22. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991;65:1107-1115.
23. Laherty CD, Hu HM, OpipariAW, Wang F, Dixit VM. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem. 1992;267:24157-24160.
24. Liebowitz D, Wang D, Kieff E. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol. 1986;58: 233-237.
25. Kaye KM, Devergne O, Harada JN, et al. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A. 1996;93:11085-11090.
26. Brodeur SR, Cheng G, Baltimore D, Thorley-Lawson DA. Localization of the major NF-κB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem. 1997;272:19777-19784.
27. Sandberg M, Hammerschmidt W, Sugden B. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol. 1997;71: 4649-4656.
28. Kieser A, Kilger E, Gires O, et al. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 1997;16:6478-6485.
29. Gires O, Kohlhuber F, Kilger E, et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 1999;18:3064-3073.
30. Chao CC, Yam WC, Chen LK, Lin-Chao S. Cloning of a functional Burkitt's lymphoma polypeptide-binding protein/78 kDa glucose-regulated protein (BiP/GRP78) gene promoter by the polymerase chain reaction, and its interaction with inducible cellular factors. Biochem J. 1992;286: 555-559.
31. Han K. An efficient DDAB-mediated transfection of Drosophila S2 cells. Nucleic Acids Res. 1996; 24:4362-4363.
32. Miller WE, Mosialos G, Kieff E, Raab-Traub N. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. J Virol. 1997;71:586-594.
33. Huber R, Schlessinger D, Pilia G. Multiple Sp1 sites efficiently drive transcription of the TATA-less promoter of the human glypican 3 (GPC3) gene. Gene. 1998;214:35-44.
34. Muller C, Yang R, Beck-von-Peccoz L, et al. Cloning of the cyclin A1 genomic structure and characterization of the promoter region: GC boxes are essential for cell cycle-regulated transcription of the cyclin A1 gene. J Biol Chem. 1999;274: 11220-11228.
35. Courey AJ, Tjian R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell. 1988; 55:887-898.
36. Kadonaga JT, Courey AJ, Ladika J, Tjian R. Distinct regions of Sp1 modulate DNA binding and transcriptional activation. Science. 1988;242: 1566-1570
37. Majello B, De Luca P, Lania L. Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains. J Biol Chem. 1997;272:4021-4026.
38. Baeuerle PA, Henkel T. Function and activation of NF-kappaB in the immune system. Annu Rev Immunol. 1994;12:141-179.
39. Baeuerle PA, Baltimore D, NF-kappa B: ten years after. Cell. 1996;87:13-20.
40. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. 1995;9:2723-2735.
41. Traenckner EB, Pahl HL, Henkel T, et al. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 1995;14:2876-2883.
42. Thanos D, ManiatisT. NF-kappa B: a lesson in family values. Cell. 1995;80:529-532.
43. Weinreb M, Day PJ, Murray PG, et al. Epstein-Barr virus (EBV) and Hodgkin's disease in children: incidence of EBV latent membrane protein in malignant cells. J Pathol. 1992;168:365-369.
44. Gumina RJ, Kirschbaum NE, Piotrowski K, Newman PJ. Characterization of the human platelet/ endothelial cell adhesion molecule-1 promoter: identification of a GATA-2 binding element required for optimal transcriptional activity. Blood. 1997;89:1260-1269.
45. Agulnick AD, Thompson JR, Ricciardi RP. An ATF/CREB site is the major regulatory element in the human herpesvirus 6 DNA polymerase promoter. J Virol. 1994;68:2970-2977.
46. Wolf I, Pevzner V, Kaiser E, et al. Downstream activation of a TATA-less promoter by Oct-2, Bob1, and NF-κB directs expression of the homing receptor BLR1 to mature B cells. J Biol Chem. 1998;273:28831-28836.
47. Ji C, Casinghino S, McCarthy TL, Centrella M. Multiple and essential Sp1 binding sites in the promoter for transforming growth factor-beta type I receptor. J Biol Chem. 1997;272:21260-21267.
48. Park GH, Plummer HK III, Krystal GW. Selective Sp1 binding is critical for maximal activity of the human c-kit promoter. Blood. 1998;92:4138-4149.
49. Saffer JD, Jackson SP, Annarella MB. Developmental expression of Sp1 in the mouse. Mol Cell Biol. 1991;11:2189-2199.
50. Dworzak MN, Fritsch G, Buchinger P, et al. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood. 1994;83:415-425.
51. Cahir McFarland ED, Izumi KM, Mosialos G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κB. Oncogene. 1999;18:6959-6964.
52. Bargou RC, Leng C, Krappmann D, et al. Highlevel nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347.
53. Hsu SM, Hsu PL. The nature of Reed-Sternberg cells: phenotype, genotype, and other properties. Crit Rev Oncog. 1994;5:213-245.
54. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100: 2961-2969.
55. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70:375-382.
56. Rothenberger S, Bachmann E, Berger C, et al. Natural 30 base pair and 69 base pair deletion variants of the LMP1 oncogene do stimulate NFκB-mediated transcription. Oncogene. 1997;14: 2123-2126.
57. Knecht H, McQuain C, Martin J, et al. Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology. Oncogene. 1996;13:947-953.
58. Gokhale DA, Evans DG, Crowther D, et al. Molecular genetic analysis of a family with a history of Hodgkin's disease and dyschondrosteosis. Leukemia. 1995;9:826-833.
59. Horwitz M, Wiernik PH. Pseudoautosomal linkage of Hodgkin disease. Am J Hum Genet. 1999; 65:1413-1422.